Effectiveness of acellular pertussis vaccine and evolution of pertussis incidence in the community of Madrid from 1998 to 2015

Zamalloa, Pello Latasa; García-Comas, Luis; Miguel, Ángel Gil de; Barranco, M.D.; Rodero, Iris Martínez; Sanz, Juan Carlos; Ordobás, María; Arce, Anthony; Garrido‐Estepa, Macarena

doi:10.1016/j.vaccine.2018.01.070

Cited by 13 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, studies report that the maternal vaccine is ineffective in preventing mild forms of the disease, as in cases classified as PLI. 4 , 6 , 11 , 24 , 25 , 26 Low VE may also be associated with the presence of multiple Bordetella pertussis clones circulating in Brazil, or different strains used in vaccine production. 4 , 13 Bacterial antigens are known for their virulence capacity and do not correspond to the antigenic profile of current vaccines.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Protective effect of exclusive breastfeeding and effectiveness of maternal vaccination in reducing pertussis-like illness

Nascimento

Baptista

Lopes

et al. 2021

Jornal de Pediatria

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“… 10 , 14 , 28 This association suggests that children of mothers vaccinated and exclusively breastfed for six months may benefit from the additional protection offered by breast milk when compared to babies born to mothers who were not vaccinated during pregnancy. 10 , 13 , 14 , 26 …”

Section: Discussionmentioning

confidence: 99%

Protective effect of exclusive breastfeeding and effectiveness of maternal vaccination in reducing pertussis-like illness

Nascimento

Baptista

Lopes

et al. 2021

Jornal de Pediatria

View full text Add to dashboard Cite

“…The currently approved aP vaccine comprises 1 to 5 purified antigens, mainly pertussis toxin (PT) and filamentous hemagglutinin (FHA). The advent of the aP vaccine has increased the public acceptance of the vaccine, thereby greatly improving immune coverage and reducing the incidence of pertussis to a record low (12)(13)(14). Although current aP vaccines have helped to reduce the morbidity and mortality associated with pertussis, they do not provide durable immunity or adequate protection against the disease caused by the currently circulating strains of B. pertussis (15,16).…”

Section: Introductionmentioning

confidence: 99%

A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussis

et al. 2023

View full text Add to dashboard Cite

Pertussis is a severe human respiratory tract infectious disease caused by Bordetella pertussis that primarily affects infants and young children. However, the acellular pertussis vaccine currently administered can induce antibody and Th2 immune responses but fails to prevent the nasal colonization and transmission of B. pertussis, causing a resurgence of pertussis, so improved pertussis vaccines are urgently needed. In this study, we created a two-component pertussis vaccine candidate containing a conjugate prepared from oligosaccharides and pertussis toxin. After demonstrating the ability of the vaccine to induce a mixed Th1/Th2/Th17 profile in a mouse model, the strong in vitro bactericidal activity and IgG response of the vaccine were further demonstrated. In addition, the vaccine candidate further induced efficient prophylactic effects against B. pertussis in a mouse aerosol infection model. In summary, the vaccine candidate in this paper induces antibodies with bactericidal activity to provide high protection, shorten the duration of bacterial existence, and further reduce disease outbreaks. Therefore, the vaccine has the potential to be the next generation of pertussis vaccines.

show abstract

“…DTwP was effective against pertussis; however, its reactogenicity and unsubstantiated concerns about risks of encephalopathy and death led to parental resistance to its use [5,6]. DTwP was ultimately replaced by less reactogenic acellular pertussis vaccines (diphtheria, tetanus, acellular pertussis vaccines [DTaP]) in the US and most industrialized countries [7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness

Zerbo

Fireman

Klein

2021

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Despite high vaccination coverage among children and adolescents, pertussis remains a public health problem, with large outbreaks occurring periodically in the US and other developed countries. Areas covered: We examine lessons learned more than 20 years after implementation of programs which use only acellular pertussis vaccines and propose avenues for possible effective use of acellular pertussis vaccine to prevent large outbreaks. Expert Opinion: Acellular pertussis vaccines were introduced more than 20 years ago, yet the incidence of pertussis has been increasing over the past decade, with periodic large outbreaks marked by notable shifts in disease burden from infants and young children toward fully vaccinated adolescents and young adults. This age shift is mainly driven by the waning of vaccine immunity. To better protect adolescents against pertussis, modification of the current acellular pertussis vaccination schedule or adoption of new vaccination strategies should be considered. For infants not yet eligible to be vaccinated, maternal vaccination against pertussis during pregnancy is an effective way to protect infants from infection, severe disease and death. Implementation of maternal vaccination programs should be encouraged in countries without one or efforts to improve coverage should be supported in countries with existing program.

show abstract

Effectiveness of acellular pertussis vaccine and evolution of pertussis incidence in the community of Madrid from 1998 to 2015

Cited by 13 publications

References 24 publications

Protective effect of exclusive breastfeeding and effectiveness of maternal vaccination in reducing pertussis-like illness

Protective effect of exclusive breastfeeding and effectiveness of maternal vaccination in reducing pertussis-like illness

A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussis

Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness

Contact Info

Product

Resources

About